Protocol Ledger

NCT05267821 · Phase II/III · RECRUITING

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Interventional Phase II/III clinical trial protocol NCT05267821 sponsored by Nationwide Children's Hospital in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-14 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05267821
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05267821
Protocol FieldVerified Registry Value
NCT IdentifierNCT05267821
Consolidated Lead SponsorNationwide Children's Hospital
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2022-06-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI